Wheeler Bio and MindImmune Therapeutics Partner to Support Alzheimer’s Prevention Program MITI-101

Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), has signed a partnership agreement with MindImmune Therapeutics to support the development of MindImmune’s lead monoclonal antibody (mAb) program, MITI-101, targeting Alzheimer’s disease.

Under the agreement, Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing services through its ModularCMC™ platform, which specializes in antibody-based therapies. MITI-101 is designed to block CD11c+ immune cells from migrating into the brain, preventing the neuroinflammation that is believed to drive Alzheimer’s and other neurodegenerative diseases. This first-in-class approach targets the trafficking of peripheral immune cells, a novel mechanism in the fight against Alzheimer’s.

Patrick Lucy, President and CEO of Wheeler Bio, expressed enthusiasm for the collaboration, highlighting the significant unmet medical need in Alzheimer’s and the benefits of their ModularCMC platform for accelerating clinical development. MindImmune previously partnered with Alloy Therapeutics for discovery, and Wheeler’s involvement will leverage economic incentives from the Wheeler-Alloy collaboration.

Stevin Zorn, President and CEO of MindImmune Therapeutics, emphasized MITI-101’s innovative strategy to combat brain inflammation by blocking innate immune cell infiltration, noting that the partnership with Wheeler Bio will help move this promising therapy into clinical trials more rapidly, offering new hope for patients and families affected by neurodegenerative diseases.